Table 1. Cancer genes included in the assay and available targeted cancer therapies
GeneSNaPshot coverageRelevant drugs: launched (developer)Relevant drugs in clinical testing (number of compounds)1
APC15%NoneNone
BRAF94%Sorafenib (Bayer HealthCare Pharmaceuticals, Onyx Pharmaceuticals)Raf inhibitors (4)
MEK inhibitors (12)
ERK inhibitor (1)
CTNNB174%NoneNone
EGFR69%Gefitinib (AstraZeneca)EGFR inhibitors (26)
Cetuximab (ImClone Systems, Merck Serono, Bristol‐Myers Squibb)
Erlotinib hydrochloride (Genentech, OSI Pharmaceuticals, Roche)
Panitumumab (Amgen)
Nimotuzumab (YM BioSciences, Biotech Pharmaceuticals, Oncoscience, Daiichi Sankyo)
Lapatinib (GlaxoSmithKline)
FLT322%Sorafenib (Bayer HealthCare Pharmaceuticals, Onyx Pharmaceuticals)FLT3 inhibitors (10)
Sunitinib (Pfizer)
JAK299%NoneJAK2 inhibitors (4)
KIT24%Imatinib mesylate (Novartis Oncology)KIT inhibitors (11)
Sorafenib (Bayer HealthCare Pharmaceuticals, Onyx Pharmaceuticals)
Sunitinib (Pfizer)
KRAS98%NoneRaf inhibitors (4)
MEK inhibitors (12)
ERK inhibitor (1)
NOTCH19%NoneNotch1/Gamma‐Secretase inhibitors (3)
NRAS97%NoneRaf inhibitors (4)
MEK inhibitors (12)
ERK inhibitor (1)
PIK3CA76%mTOR inhibitors:
Sirolimus (Wyeth Pharmaceuticals)PI3K inhibitors (10)
Everolimus (Novartis Pharmaceuticals)PKB/AKT inhibitors (6)
Temsirolimus (Wyeth Pharmaceuticals)mTOR inhibitors (13)
PTEN15%mTOR inhibitors:
Sirolimus (Wyeth Pharmaceuticals)PI3K inhibitors (10)
Everolimus (Novartis Pharmaceuticals)PKB/AKT inhibitors (6)
Temsirolimus (Wyeth Pharmaceuticals)mTOR inhibitors (13)
TP5329%NoneNone
  • 1 Cancer trials.